Articles On NeuroScientific Biopharmaceuticals (ASX:NSB)

ASX up 0.56% or 49.1 points with solid breadth (122/200 stocks rising) Materials, banks provide momentum while energy retreats Seven of 11 sectors in the red, but solid support from Resources and Banks indices   Market climbs metals ladde...

NeuroScientific Biopharmaceuticals’ StemSmart cell therapy has delivered real-world promise for those living with chronic Crohn’s disease, validating the platform and setting the stage for later-phase trials.

Shares in Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) have rocketed more than 50% higher after the company announced positive clinical trial results for a treatment for Crohn's Disease. The biotechnology company, which focuses on...

highlights Global markets set the tone ahead of the local open Commodities and sentiment remain closely watched Select ASX-listed companies draw early attention Global cues, commodities, and select ASX-listed companies...

ASX 200 dips three points, or 0.03% Even split with six sectors in the red Info tech, banks and materials weigh heavy as energy recovers   Market crabwalks through first full week On the whole, the ASX 200 traded mostly sideways in the fi...

In a tight race, drug developer Nyrada so far is this year’s star performer with almost an eightfold gain Diagnostic house Lumos and imagers Artrya and 4D Medical also have run a good race, with their US plans unfolding to script Nyrada ch...

NeuroScientific Biopharmaceuticals has dosed a fourth Crohn’s disease patient with its StemSmart stem-cell therapy, in a step towards phase two trials of a novel treatment for the debilitating bowel condition.

Integral Diagnostics and Medadvisor have new CEOs after the latest round of changes at the top Mayne’s refrain: let the Takeovers Panel decide It’s a case of the MEGnificent Five as Compumedics sells another brain-scanning device in China...

Biotechs are adopting ‘plan B’ strategies by purchasing complementary drug programs Antivirals house Biotron hopes to shake up the moribund anaesthetic drug sector Other companies with interesting diversions include Island Pharmaceuticals,...

Emerging companies connected with investors at Jane Morgan Management’s Investor Lunch Pitches showcased emerging growth sector to institutional and high-net-worth investors Mining and biotech companies presented their innovation, progress...

NeuroScientific Biopharmaceuticals’ stem cell therapy helped 80% of a small group of renal patients retain donor kidneys and showed safety in transplants, supporting a push into the US$7.2B immunotherapy market

MoneyTalks is Stockhead’s drill down into what stocks investors are looking at right now. We tap our list of experts to hear what’s hot, their top picks and what they’re looking out for. Today we hear from Australia’s Summit Biotech Fund ma...

Highlights: S&P/ASX 200 rose steadily in July Healthcare sector posted a sharp rebound Select AI and mineral stocks delivered standout gains The s&p 200 gained ground in July, riding a wave of global optimism a...

Stem cell pioneer NeuroScientific Biopharmaceuticals is transferring its patented StemSmart technology to one of Australia’s biggest and most experienced manufacturers to scale up clinical-grade production.

NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment. Melbourne-based exec Nathan Smith is bringing his strategic nous as CEO, ahead of the release of the company’s stem cell tech.

NeuroScientific Biopharmaceuticals has appointed a senior WA oncologist and haematologist as chief medical officer. Catherine Cole’s experience will help the company roll out its innovative stem cell therapy.

Highlights ASX opens slightly lower with mixed sector performance Synergy reveals MoU to clarify ASX inquiry Several microcap stocks show strong early trading momentum The Australian share market opened marginally lowe...

NeuroScientific Biopharmaceuticals (ASX: NSB) is investigating the use of its newly-acquired StemSmart stem cell technology for complex indications including refractory Crohn’s disease and steroid-refractory GVHD (graft-versus-host disease)...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

NeuroScientific Biopharmaceuticals has ventured into stem cell therapy with a $5.1M purchase of unlisted Perth-based company Isopogen, whose tech shows potential in autoimmune disease and transplant medicine.

Orthocell says its Remplir nerve device blitzes the stitches Singular Health inks US physician network deal Clarity clearly is undervalued, say brokers   Among other auspicious events, the 19th of June marks the end of slavery in the US,...

Global pharmaceutical leader Herwig Janssen appointed Tryptamine non-executive chairman Janssen held senior leadership roles with multinational pharmaceutical company Johnson & Johnson Chris Ntoumenopoulos will transition to role of ex...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Highlights: The ASX starts the day with minimal movement, reflecting uncertainty in early trading. Pharma and semiconductor tariff discussions weigh on global markets, while the US faces a downward trend. ASX stocks like Neu...

ASX climbs 0.3pc before falling flat to end at -0.04pc Financial and consumer staples sectors outperform to limit losses Energy plummets more than 2.5pc as oil outlook darkens   Between looming pharmaceuticals and semiconductor tariffs an...

NeuroScientific Biopharmaceuticals (ASX: NSB) has announced it will acquire private company Isopogen WA and its StemSmart patented stem cell technology for the manufacture of mesenchymal stromal cells (MSC). The company will incorporate the...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnes...

NeuroScientific Biopharmaceuticals (ASX:NSB) has received feedback and guidance from the US FDA on its planned non-clinical and clinical development program of EmtinB as a treatment for adults with advanced glaucoma via a pre-IND me...

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Neuroscientific Biopharma to have a pre-IND meeting with US FDA The NSB stock price jumped as high as 30pc this morning Artrya signs first deal in Australia   NSB to have meeting with FDA NeuroScientific Biopharma (ASX:NSB) jumped as high...

The ASX200 finished off the first day of December down 0.2 of a percent – with all sectors, except energy, losing some ground.  In the Green Retail conglomerate Premier Investments (ASX:PMV) gained 2.8 per cent today following its Ann...

King Charles III loses coveted job of lurking on Australia’s $5 notes Adani down in the dumps after binning its multi-billion dollar cake sale Spacetalk heads for the moon on news the company’s found itself a new CEO   The ASX has had yet...

NeuroScientific Biopharmaceuticals (NSB) pockets a $3.7 million tax refund from the Australian Federal Government. The company received the government incentive payment for research and development undertaken during the 2021/2022 financi...

NSB files new patent in Australia Imugene doses first patient in Phase 1 trial Cronos and MGC Pharma give sales update   NSB announces patent filing in Australia NeuroScientific Biopharma (ASX:NSB) announced a new patent filing in Austral...

NeuroScientific Biopharmaceuticals (NSB) appoints Paul Rennie as interim CEO, nearly three months after former CEO Matt Liddelow resignedPaul Rennie is currently NSB’s Chair and will remain in both positions, but take more of an “active rol...

The ASX is poised to open higher on Wednesday after a rally in New York Oil prices higher as Saudi said OPEC+ wasn’t considering output increase Crypto broker Genesis near bankcruptcy The ASX is set to open higher on Wednesday after a bro...

NeuroScientific Biopharmaceuticals (NSB) CEO and Managing Director Matt Liddelow resigns from the company, effective immediatelyThe news comes just 48 hours after NSB’s announcement its phase one clinical trial for EmtinB was rejected by th...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Neuroscientific Biopharmaceuticals (NSB) astounds investors this morning with the news its phase one clinical trial for EmtinB has been rejectedThe company was informed by the Human Research Ethics Committee (HREC) of the rejection, citing...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

Neuroscientific Biopharma’s receipt of $1.13m in R&D tax incentive from the government is timely as it prepares for an early phase clinical trial of lead asset, EmtinB.  Australian drug development company Neuroscientific Biopharmaceuti...

Neuroscientific Biopharmaceuticals CEO and MD Matthew Liddelow says the company has entered one of the most exciting stages of its existence – successfully transitioning into clinical trials for its lead drug, peptide based compound, EmtinB...

Neuren’s Phase 2 clinical trial is now open for enrolment Neuroscientific submits an ethics approval request for Phase 1 trial Cannabis play Little Green Pharma signs $2m supply deal Neurological disorders specialist Neuren Pharmaceutical...

NeuroScientific Biopharmaceuticals (ASX:NSB) says it has submitted an application for Human Research Ethics Committee approval to commence a Phase I clinical trial of its lead drug candidate EmtinB.

NeuroScientific Biopharmaceuticals (NSB) recruits its first subject for an early-phase clinical trial The clinical stage drug development company announced the recruitment for its trial for lead drug candidate, EmtinB to treat neurodegener...

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB.

NeuroScientific Biopharmaceuticals (ASX:NSB) has announced positive preliminary results of lead drug candidate EmtinB in an animal model of Multiple sclerosis.

Highlights Investors are looking at clean energy stocks as the world is increasingly shifting from non-renewable to renewable energy sources. Australia intends to achieve a target of net-zero carbon emissions by 2050. The share prices...

Highlights NeuroScientific has received positive preliminary results from a study of its lead drug candidate EMTINB™ on multiple sclerosis. Mice treated with 10mg/kg and 20mg/kg doses of EmtinB™ constantly reached lower clinical scores...